About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Tg(GFAP-cre/ERT2)13Kdmc
transgene insertion 13, Ken D McCarthy
MGI:3712447
Summary 2 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
 		Npc1m1N/Npc1tm1.1Apl
Tg(GFAP-cre/ERT2)13Kdmc/0 		B6J.Cg-Npc1m1N/Npc1tm1.1Apl Tg(GFAP-cre/ERT2)13Kdmc MGI:5925344
cn2
 		Slc1a2tm1.1Pros/Slc1a2tm1.1Pros
Tg(GFAP-cre/ERT2)13Kdmc/0 		involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6 MGI:5771812


Genotype
MGI:5925344
cn1
Allelic
Composition		 Npc1m1N/Npc1tm1.1Apl
Tg(GFAP-cre/ERT2)13Kdmc/0
Genetic
Background		 B6J.Cg-Npc1m1N/Npc1tm1.1Apl Tg(GFAP-cre/ERT2)13Kdmc
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Npc1m1N mutation (3 available); any Npc1 mutation (74 available)
Npc1tm1.1Apl mutation (0 available); any Npc1 mutation (74 available)
Tg(GFAP-cre/ERT2)13Kdmc mutation (1 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
normal phenotype
no abnormal phenotype detected ( J:176888 )
• mice treated with tamoxifen at 6 weeks of age exhibit normal weight gain, motor performance, and survival and do not show Purkinje cell loss, axonal spheroids, demyelination, or activated astrocytes or microglia in the cerebellum, and no functional alterations in synaptic transmission




Genotype
MGI:5771812
cn2
Allelic
Composition		 Slc1a2tm1.1Pros/Slc1a2tm1.1Pros
Tg(GFAP-cre/ERT2)13Kdmc/0
Genetic
Background		 involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Slc1a2tm1.1Pros mutation (1 available); any Slc1a2 mutation (40 available)
Tg(GFAP-cre/ERT2)13Kdmc mutation (1 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:221590 )
• following postnatal tamoxifen treatment (P5-P9), mice die significantly earlier than control mice, with a median survival at 23 weeks of age

growth/size/body
slow postnatal weight gain ( J:221590 )
• tamoxifen-treated mice gain significantly less weight than controls from 10 weeks of age

behavior/neurological
behavior/neurological phenotype ( J:221590 )
N
• at 28-67 weeks of age, tamoxifen-treated mice show no significant differences in total SHIRPA scores relative to control mice
seizures ( J:221590 )
• tamoxifen-treated mice show more electroencephalographic seizure events than controls
• however, no spontaneous clinical seizures are observed

nervous system
nervous system phenotype ( J:221590 )
N
• at 14-19 weeks of age, tamoxifen-treated mice show only a minor, insignificant decrease in the uptake of L-[3H]glutamate (~15%) and D-[3H]aspartate (~13%) into crude forebrain synaptosomes relative to controls
seizures ( J:221590 )
• tamoxifen-treated mice show more electroencephalographic seizure events than controls
• however, no spontaneous clinical seizures are observed
abnormal brain wave pattern ( J:221590 )
• tamoxifen-treated mice show a significantly higher number of automatically detected spike-trains (electroencephalographic seizures) per 20 min of scalp EEG recording relative to controls (18.7 +/- 7.2 vs 1.9 +/- 0.5)




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
10/29/2024
MGI 6.24 		The Jackson Laboratory